- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02182245
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
July 17, 2014 updated by: Boehringer Ingelheim
A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female patients with the following histologically confirmed advanced gynaecological malignancies: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma or vulvular carcinoma
- Metastatic disease or locally advanced disease that is not resectable with curative intention
- Indication for combination chemotherapy with paclitaxel/carboplatin as judged by the investigator
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Life expectancy of at least 6 months
- Written informed consent that is not consistent with ICH-GCP (International Conference on Harmonisation - Good Clinical Practice) guidelines and local requirements
Exclusion Criteria:
- Participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study
- Radiotherapy within 4 weeks before the start of therapy
- Chemotherapy, immunotherapy or hormonal therapy (with the exception of hormonal replacement therapy) within 4 weeks before the start of the therapy
- Patients with germ cell tumours, early stage ovarian cancer (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] stage I-IIA), primary cervical cancer (FIGO I-III), primary endometrial cancer (FIGO I-III) or borderline tumours
- Patients with known brain metastases
- Symptomatic bowel obstruction or known or suspected malabsorption
- Patients with pericardial effusion which is haemodynamically relevant
- Other malignancy diagnosed within the past 5 years (other than non-melanomatous skin cancer or cervical carcinoma in situ)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study medication
- History of haemorrhagic or thrombotic event (including transient ischemic attacks) in the past 6 months
- Concurrent therapeutic anticoagulation or anti-platelet therapy (except chronic low dose daily acetylsalicylic acid <300 mg)
- Major injuries and surgeries within the past 3 weeks, planned surgical procedures during the trial, incomplete wound healing
- Known hypersensitivity to paclitaxel, carboplatin, BIBF 1120 or any of their excipients or vehicles such as polyoxyethylated castor oil
- Clinically significant peripheral polyneuropathy (>CTCAE grade 1) which precludes therapy with paclitaxel
- Absolute neutrophil count (ANC) <1500/μL, platelet count <100000/μL, or haemoglobin <9 mg/dL
- Total bilirubin >1.5 mg/dL (26 μmol/L), ALT (Alanine aminotransferase) and/or AST (Aspartate aminotransferase) >1.5 x the upper limit of normal (ULN)
- Serum creatinine >1.5 mg/dL (>132 μmol/L)
- Persistent gross haematuria
- Pregnancy or breast feeding
- Women with childbearing potential and who are sexually active and unwilling to use a medically acceptable method of contraception (oral contraceptive, diaphragm with spermicide, intrauterine device, condom with spermicide)
- Known or suspected active drug or alcohol abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination Therapy
|
|
Experimental: Monotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose (MTD) of BIBF 1120
Time Frame: up to 126 days
|
up to 126 days
|
Incidence and intensity of adverse events according to the CTCAE (Common terminology criteria for adverse events Version) version 3.0 with increasing doses of BIBF 1120
Time Frame: up to 9 months
|
up to 9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective tumour response after treatment with BIBF 1120 in combination with carboplatin and paclitaxel in evaluable patients
Time Frame: up to 9 months
|
up to 9 months
|
Cancer antigen 125 (CA-125) response
Time Frame: Day 1 of each treatment period
|
Day 1 of each treatment period
|
Time to tumour progression (time from treatment start to the time of documented tumour progression)
Time Frame: up to 9 months
|
up to 9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2005
Primary Completion (Actual)
January 1, 2007
Study Registration Dates
First Submitted
July 2, 2014
First Submitted That Met QC Criteria
July 2, 2014
First Posted (Estimate)
July 8, 2014
Study Record Updates
Last Update Posted (Estimate)
July 18, 2014
Last Update Submitted That Met QC Criteria
July 17, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Female
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Protein Kinase Inhibitors
- Carboplatin
- Paclitaxel
- Nintedanib
Other Study ID Numbers
- 1199.6
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genital Neoplasms, Female
-
The University of Texas Medical Branch, GalvestonM.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaboratorsActive, not recruitingMalignant Neoplasms of Female Genital OrgansUnited States
-
M.D. Anderson Cancer CenterEli Lilly and Company; AstraZenecaActive, not recruitingMalignant Neoplasms of Female Genital OrgansUnited States
-
Northwestern UniversityCompletedMalignant Female Reproductive System NeoplasmUnited States
-
M.D. Anderson Cancer CenterCompletedMalignant Female Reproductive System NeoplasmUnited States
-
University Hospital TuebingenUniversity Hospital Heidelberg; University Hospital Freiburg; University of HomburgRecruitingUterine NeoplasmsGermany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Female Reproductive System Neoplasm | CaregiverUnited States
-
Karolinska InstitutetRegion SkaneRecruitingNeoplasms | Neoplasms by Site | Cervical Cancer | Uterine Neoplasms | Uterine Diseases | Genital Diseases, Female | Uterine Cervical Neoplasm | Uterine Cervical Disease | Genital Neoplasm, Female | Genital NeoplasmSweden
-
Ding MaShandong University; Huazhong University of Science and Technology; Zhejiang...Active, not recruitingEndometrial NeoplasmsChina
-
Ding MaShandong University; Huazhong University of Science and Technology; Zhejiang...Active, not recruiting
-
Mayo ClinicRecruitingAdvanced Malignant Female Reproductive System NeoplasmUnited States
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
MEI Pharma, Inc.CompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
-
Medical Research CouncilEuropean Organisation for Research and Treatment of Cancer - EORTCCompletedTesticular Germ Cell TumorUnited Kingdom, Canada, Norway, Netherlands, South Africa, Brazil, Finland
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States